Preview

User

Not a user? Register with this site Forgot your password?

PULMONOLOGIYA

Advanced search

COVID-19 in cystic fibrosis patients

https://doi.org/10.18093/0869-0189-2020-30-5-544-552

Abstract

Since the beginning of the COVID-19 epidemic, the European cystic fibrosis society (ECFS) has decided to launch a special ECFS-COVID-19 program to collect information on the of COVID-19 characteristics in the patients with cystic fibrosis (CF). The results of the program should help timely and efficiently provide the patients with CF with the necessary care. Initially, it was assumed that COVID-19 would be severe in CF patients. The aim. Тo assess the prevalence and characteristics of COVID-19 in patients with cystic fibrosis (CF) in the Russian Federation (RF). Methods. 6 cases (4 children and 2 adults) of COVID-19 in Russian CF patients were analyzed. Results. There are 405,843 infected with SARS-CoV-2 in Russia, the incidence of coronavirus infection in Russia was 1.4 cases per 1 thousand people. According to the Ministry of Health of the RF, as of December 2019, there were 3,931 patients with CF (2,823 children and 1,108 adults). The incidence of COVID-19 was 1.5 per 1000 patients with CF (1.4 : 1,000 for children and 1.8 : 1,000 for adults). The incidence was not higher than in the General population. The diagnosis of COVID-19 was confirmed in 4 boys and 2 women, 3 of the patients were infected with Pseudomonas aeruginosa and 2 – with Achromobacter spp. Mild disease was seen in 5 patients including all the children. Pneumonia was registered in 3 patients. One child with COVID-19 had abdominal syndrome. 2 patients – 1 adult and 1 child – needed in-patient care. Additional antibiotics were given to 4 patients, 2 of them received i/v antibiotics. One adult patient was on the lung transplantation waiting list. This woman had long-term oxygen therapy and BiPAP noninvasive respiratory support before the infection with SARS-CoV-2, FEV1 was 24 %pred. Conclusion. Despite the fact that patients with CF are at risk of severe COVID-19, to date, in the described cases, COVID-19 infection has not led to a significant deterioration of the symptoms of CF. Not a single fatal outcome in Russian patients with CF has been recorded.

About the Authors

E. I. Kondratyeva
Academician N.P.Bochkov Federal Medical Genetic Academic Center, Russian Academy of Science
Russian Federation

Elena I. Kondrat’eva – Doctor of Medicine, Professor, Head of Research and Clinical Division of Cystic Fibrosis

ul. Moskvorech’e 1, Moscow, 1115478
tel.: (495) 587-33-66


S. A. Krasovsky
Academician N.P.Bochkov Federal Medical Genetic Academic Center, Russian Academy of Science; Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation

Stanislav A. Krasovskiy – Candidate of Medicine, Senior Researcher of Cystic Fibrosis Department, Research and Clinical Division of Cystic Fibrosis, Academician N.P.Bochkov Federal Medical Genetic Academic Center, Senior Researcher of Cystic Fibrosis Laboratory, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia. SPIN: 33856489; Author ID: 688178

ul. Moskvorech’e 1, Moscow, 1115478
Orekhovyy bul’var 28, Moscow, 115682
tel.: (926) 273-76-34


N. Yu. Kashirskaya
Academician N.P.Bochkov Federal Medical Genetic Academic Center, Russian Academy of Science
Russian Federation

Nataliya Yu. Kashirskaya – Doctor of Medicine, Professor, Principal Researcher, Laboratory of Genetic Epidemiology

ul. Moskvorech’e 1, Moscow, 1115478
tel.: (495) 111-03-03


E. L. Amelina
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation

Elena L. Amelina – Candidate of Medicine, Head of the Cystic Fibrosis Laboratory

Orekhovyy bul’var 28, Moscow, 115682
tel.: (926) 205-03-91


E. K. Zhekaite
Academician N.P.Bochkov Federal Medical Genetic Academic Center, Russian Academy of Science
Russian Federation

Elena K. Zhekayte – Researcher, Research and Clinical Division of Cystic Fibrosis

ul. Moskvorech’e 1, Moscow, 1115478
tel.: (499) 612-86-07


V. D. Sherman
Academician N.P.Bochkov Federal Medical Genetic Academic Center, Russian Academy of Science
Russian Federation

Viktoriya D. Sherman – Candidate of Medicine, Leading Researcher, Research and Clinical Division of Cystic Fibrosis

ul. Moskvorech’e 1, Moscow, 1115478
tel.: (499) 612-86-07


O. I. Simonova
Federal Academic Centre of Children’s Health, Healthcare Ministry of Russia; Morozov State Pediatric Teaching Hospital, Moscow Healthcare Department; I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia
Russian Federation

Ol’ga I. Simonova – Doctor of Medicine, pediatrician, Head of the Pulmonary Department, Federal Academic Centre of Children’s Health, Healthcare Ministry of Russia, Head of Cabinet of Cystic Fibrosis, Morozov State Pediatric Teaching Hospital, Moscow Healthcare Department, Professor, I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia

Lomonosovskiy pr. 2, build. 1, Moscow, 119991
Chetvertyy Dobryninskiy per. 1/9, Moscow, 119049
ul. Trubetskaya 8, build. 2, Moscow, 119991
tel.: (910) 468-87-89


Yu. V. Gorinova
Federal Academic Centre of Children’s Health, Healthcare Ministry of Russia
Russian Federation

Yuliya V. Gorinova – Candidate of Medicine, Senior Researcher, Laboratory of Rare and Hereditary Diseases in Children

Lomonosovskiy pr. 2, build. 1, Moscow, 119991
tel.: (499) 134-24-21


E. V. Boitsova
Saint Petersburg State Pediatric Medical University, Healthcare Ministry of Russia
Russian Federation

Evgeniya V. Boitsova – Doctor of Medicine, Professor, Department of Propedeutics of Childhood Diseases

ul. Litovskaya 2, Saint Petersburg, 194100
tel.: (911) 739-00-22


M. A. Mukhina
Morozov State Pediatric Teaching Hospital, Moscow Healthcare Department:
Russian Federation

Marуа A. Mukhina – Pediatrician, Medical and Genetic Department, Cystic Fibrosis Cabinet

Chetvertyy Dobryninskiy per. 1/9, Moscow, 119049
tel.: (916) 580-69-86


I. N. Butyugina
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation

Irina N. Butyugina – Researcher, Cystic Fibrosis Laboratory

Orekhovyy bul’var 28, Moscow, 115682
tel.: (926) 366-95-36


M. A. Makarova
N.I.Pirogov Federal Russian National Research Medical University, Healthcare Ministry of Russia
Russian Federation

Marina A. Makarova – Candidate of Medicine, Associate Professor of Department of Hospital Therapy, Pediatric Faculty

ul. Ostrovityanova 1, Moscow, 117997
tel.: (499) 780-08-50


A. B. Malakhov
I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia
Russian Federation

Aleksandr B. Malakhov – Doctor of Medicine, Professor, Chief Pediatric Pulmonologist, Professor of the Department of Childhood Diseases

ul. Trubetskaya 8, build. 2, Moscow, 119991
tel.: (985) 970-73-11


References

1. Guan W., Ni Z., Hu Yu et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020; 382 (18): 1708–1720. DOI: 10.1056/NEJMoa2002032.

2. Kapranov N.I., Kashirskaya N.Yu., eds. [Cystic Fibrosis]. Moscow: Medpraktika-M; 2014 (in Russian).

3. World Health Organization. [Coronavirus disease (COVID-19): frequently asked questions]. Available at: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019/advice-for-public/q-a-coronaviruses [Accessed: June 2, 2020] (in Russian).

4. Amelina E.L., N.Ju. Kashirskaya N.Yu., Kondrat’eva E.I. et al. (eds.) [Register of cystic fibrosis patients in the Russian Federation. 2018 year]. Moscow: Medpraktika-M; 2020 (in Russian).

5. Pukhal’skiy A.L., Shmarina G.V., Pukhal’skaya D.D. [Features of the inflammatory process in patients with cystic fibrosis]. Pul’monologiya. 2006; (Suppl.): 81–83 (in Russian).

6. Glybochko P.V., Fomin V.V., Avdeev S.N. et al. [Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia]. Klinicheskaya farmakologiya i terapiya. 2020; 29 (2): 21–29. DOI: 10.32756/0869-54902020-2-21-29 (in Russian).

7. Barnes B.J., Adrover J.M., Baxter-Stoltzfus A. et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 2020; 217 (6): e20200652. DOI: 10.1084/jem.20200652.

8. ECFS. 2017 Patient Registry Annual Data Report. Available at: https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report2017_v1.3.pdf [Accessed: June 2, 2020].

9. Cosgriff R., Ahern S., Bell S.C. et al. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. J. Cyst. Fibros. 2020; 19 (3): 355–358. DOI: 10.1016/j.jcf.2020.04.012.

10. Colombo C., Burgel P.R., Gartner S. et al. Impact of COVID-19 on people with cystic fibrosis. Lancet Respir. Med. 2020; 8 (5): е35–36. DOI: 10.1016/S2213-2600(20)30177-6.

11. Ministry of Health of the Russian Federation. [The Temporary Guidelines: Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 6 (April 28, 2020)]. Available at: https://static1.rosminzdrav.ru/ [Accessed: June 2, 2020] (in Russian).

12. ECFS. COVID-CF project in Europe. Available at: https://www.ecfs.eu/covid-cf-project-europe [Accessed: June 2, 2020].

13. Dong Y., Mo X., Hu Y. et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 2020; 145 (6): e20200702. DOI: 10.1542/peds.2020-0702.


Review

For citations:

Kondratyeva E.I., Krasovsky S.A., Kashirskaya N.Yu., Amelina E.L., Zhekaite E.K., Sherman V.D., Simonova O.I., Gorinova Yu.V., Boitsova E.V., Mukhina M.A., Butyugina I.N., Makarova M.A., Malakhov A.B. COVID-19 in cystic fibrosis patients. PULMONOLOGIYA. 2020;30(5):544-552. https://doi.org/10.18093/0869-0189-2020-30-5-544-552

Views: 1939


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)

The Publications Office Address
ul. Odinnadtsataya Parkovaya 32, build. 4, Moscow, 105077, Russia
Tel.: 8-925-744-72-98
E-mail: pulmo@pulmonology.ru

Processing of personal data
supported by NEICON (Elpub lab)